JAK2(V617F) reversible activation shows an essential requirement for JAK2(V617F) in myeloproliferative neoplasms (MPNs) Meeting Abstract

  

Authors:	Dunbar, A.; Bowman, R. L.; Park, Y.; Izzo, F.; Myers, R. M.; Karzai, A.; Kim, W. J.; Maestre, I. F.; Waarts, M. R.; Nazir, A.; Xiao, W.; Brodsky, M.; Farina, M.; Cai, L.; Cai, S. F.; Wang, B.; An, W.; Yang, J.; Mowla, S.; Eisman, S. E.; Mishra, T.; Houston, R.; Guzzardi, E.; Martinez Benitez, A. R.; Viny, A. D.; Koche, R.; Landau, D. A.; Levine, R. L.
Abstract Title:	JAK2(V617F) reversible activation shows an essential requirement for JAK2(V617F) in myeloproliferative neoplasms (MPNs)
Meeting Title:	64th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	140
Issue:	Suppl. 1
Meeting Dates:	2022 Dec 10-13
Meeting Location:	New Orleans, LA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2022-11-15
Start Page:	803
End Page:	804
Language:	English
ACCESSION:	WOS:000893223200330
DOI:	10.1182/blood-2022-164827
PROVIDER:	wos
Notes:	Meeting Abstract -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/204936